Drug recall · December 26, 2018
Nevirapine Extended Release Tablets recall
Why: Failed Dissolution Specifications.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Nevirapine Extended Release Tablets, 400 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd. Verna Goa, India, Manufactured for: Cipla USA Inc. 9100 S Dadeland Blvd., Suite 1500 Miami, FL 33156, NDC 69097-403-02
- Lots / codes
Lot #: GG80257, Exp. 12/2019
- Quantity
- 4800 bottles
- Company
- Cipla Limited, Vasco Da Gama
- Distribution
- Nationwide within the United States
- Initiated
- December 14, 2018 · Voluntary: Firm initiated
- Classified
- January 16, 2019
- Reported
- December 26, 2018
- Ended
- July 8, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nevirapine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.